These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17538545)

  • 1. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.
    McComsey GA; O'Riordan M; Setzer B; Lebrecht D; Baron E; Walker UA
    Eur J Clin Nutr; 2008 Aug; 62(8):1031-7. PubMed ID: 17538545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
    McComsey GA; O'Riordan M; Choi J; Libutti D; Rowe D; Storer N; Harrill D; Gerschenson M
    Antivir Ther; 2012; 17(2):347-53. PubMed ID: 22293126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
    McComsey GA; Walker UA; Budhathoki CB; Su Z; Currier JS; Kosmiski L; Naini LG; Charles S; Medvik K; Aberg JA;
    AIDS; 2010 Oct; 24(16):2507-15. PubMed ID: 20827170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
    Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A;
    HIV Med; 2010 Sep; 11(8):493-501. PubMed ID: 20236365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
    McComsey GA; Lo Re V; O'Riordan M; Walker UA; Lebrecht D; Baron E; Mounzer K; Frank I
    Clin Infect Dis; 2008 Apr; 46(8):1290-6. PubMed ID: 18444869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status.
    Shikuma CM; Gerschenson M; Chow D; Libutti DE; Willis JH; Murray J; Capaldi RA; Marusich M
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1255-62. PubMed ID: 18844460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients.
    Banasch M; Goetze O; Knyhala K; Potthoff A; Schlottmann R; Kwiatek MA; Bulut K; Schmitz F; Schmidt WE; Brockmeyer NH
    AIDS; 2006 Jul; 20(11):1554-6. PubMed ID: 16847412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
    Rabing Christensen E; Stegger M; Jensen-Fangel S; Laursen AL; Ostergaard L
    Clin Infect Dis; 2004 Nov; 39(9):1371-9. PubMed ID: 15494915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
    McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
    AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
    Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
    AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
    Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
    AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
    Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
    Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.
    McComsey GA; Libutti DE; O'Riordan M; Shelton JM; Storer N; Ganz J; Jasper J; Harrill D; Gerschenson M
    Antivir Ther; 2008; 13(5):715-22. PubMed ID: 18771055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.